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Abstract
AIM: To analyze contrast-enhanced ultrasound (CEUS) 
features of histologically proven hepatic epithelioid 
hemangioendothelioma (HEHE) in comparison to other 
multilocular benign focal liver lesions (FLL).
METHODS: Twenty-five patients with histologically 
proven HEHE and 45 patients with histologically proven 
multilocular benign FLL were retrospectively reviewed. 
Four radiologists assessed the CEUS enhancement 
pattern in consensus.
RESULTS: HEHE manifested as a single (n  = 3) 
or multinodular (n  = 22) FLL. On CEUS, HEHE 
showed rim-like (18/25, 72%) or heterogeneous 
hyperenhancement (7/25, 28%) in the arterial phase 
and hypoenhancement (25/25, 100%) in the portal 
venous and late phases (PVLP), a sign of malignancy. 
Eighteen patients showed central unenhanced areas 
(18/25, 72%); in seven patients (7/25, 28%), more 
lesions were detected in the PVLP. In contrast, 
all patients with hemangioma and focal nodular 
hyperplasia showed hyperenhancement as the most 
distinctive feature (P  < 0.01).
CONCLUSION: CEUS allows for characterization of 
unequivocal FLL. By analyzing the hypoenhancement in 
the PVLP, CEUS can determine the malignant nature of 
HEHE. 
Key words: Guidelines; Recommendations; Liver 
tumor; Biopsy; Liver transplantation Contrast enhanced 
ultrasound
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: In this retrospective study, a large cohort of 
very rare histologically proven hemangioendothelioma 
(HEHE) was evaluated. Contrast-enhanced ultrasound 
(CEUS) allowed for improved detection of multilocular 
HEHE. HEHE showed typical enhancement patterns 
on CEUS. Therefore, CEUS can help to determine the 
malignant nature of HEHE. 
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INTRODUCTION
Hepatic epithelioid hemangioendothelioma (HEHE) 
is a rare vascular neoplasm of endothelial origin with 
primary liver involvement and is characterized by 
the presence of epithelioid endothelial cells[1]. Weiss 
and Enzinger first reported 41 patients with this 
unique tumor in 1982[2]. This tumor is histologically 
characterized by an epithelial appearance and the 
endothelial nature of the tumor cells[3]. Currently no 
more than 200 patients with HEHE have been reported 
since its first description, and most of the studies were 
small series[4,5]. 
No definite etiopathogenetic factors, apart from 
an association with oral contraceptives, trauma, 
and exposure to vinyl chloride, have to date been 
ascribed to HEHE[1,6]. The tumor generally affects 
adults, with a strong female predominance and a 
peak incidence occurring between 30 and 40 years 
of age. The clinical manifestations and laboratory 
data of HEHE are nonspecific, usually presenting with 
general symptoms, such as right upper quadrant pain 
or weight loss. Some patients may present with liver 
failure, Budd-Chiari syndrome, or portal hypertension, 
while others may be asymptomatic. Its clinical course 
and prognosis are variable and unpredictable[7]. Due 
to its nonspecific clinical manifestations and prolonged 
clinical course, establishing diagnosis even with 
histopathological findings can often be challenging[8]. 
HEHE carries intermediate malignant potential, 
and transplantation may provide a long term cure[9]. 
Therefore, the recognition of the imaging features of 
this rare neoplasm may be helpful for the detection and 
further surgical treatment of this potentially curable 
disease. In addition, it is important to distinguish 
HEHE from other primary and secondary benign 
and malignant hepatic tumors, such as atypical 
(multilobulated) hemangioma and hemangiomatosis, 
hepatocellular adenoma and hepatocellular carcinoma, 
intrahepatic cholangiocarcinomas, lymphoma, and 
liver metastases[10]. Radiologists should be aware of 
its imaging findings and raise suspicion in the proper 
clinical setting[8,11]. 
Conventional ultrasound is the most commonly 
used imaging method for real time diagnosis of FLL. 
However, the most frequent imaging findings of 
multilocular HEHE are nonspecific[11]. Often, multiple 
HEHE on conventional ultrasound might be difficult to 
differentiate from other atypical multilocular FLLs[12,13]. 
As a result, the final diagnosis of HEHE depends on 
biopsy and histological findings[14,15].
Contrast enhanced ultrasound (CEUS) allows for 
the differentiation of most benign and malignant 
liver tumors in the portal venous and late phases 
(PVLP). This finding was summarized in the European 
Federation of Societies for Ultrasound in Medicine and 
Biology guidelines and recommendations for the use 
of CEUS in liver[16,17]. Benign FLLs are typically iso- 
or hyperenhancing in the PVLP; whereas malignant 
primary and secondary liver tumors almost always 
show hypoenhancement in the PVLP, since they do 
not contain the respective specific hepatic vessels. 
This hypoenhancement in the PVLP is decisive for 
determining if a lesion should be biopsied[18,19]. In 
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4742 May 21, 2016|Volume 22|Issue 19|WJG|www.wjgnet.com
addition, CEUS findings of HEHE have not been well 
addressed. Therefore, the aim of our study is to 
analyze the CEUS features of histologically proven 
HEHE and to compare these features to those of other 
multilocular benign FLLs, including hemangiomas and 
focal nodular hyperplasia (FNH), since they are the 
most important for differential diagnosis. We assessed 
the clinical value of CEUS to define the malignant 
nature of the disease with hypoenhancement in the 
PVLP. To our best knowledge, this is the first report on 
the CEUS features of HEHE.
MATERIALS AND METHODS
Patients
Hemangioendothelioma: Between September 2004 
and October 2015, 25 patients (eight male, 17 female, 
mean age 46 ± 14 years; range 24-78 years) were 
retrospectively analyzed. In this retrospective study, 
lesions were histologically proven by hepatic surgery (n 
= 6) or by 18-gauge core needle biopsy (n = 19). 
Three patients had a single FLL, whereas 22 
patients had multiple FLLs (Table 1). In patients with 
multiple FLLs, the selected lesions were those in which 
biopsies had been performed.
Multilocular hemangioma and FNH
Forty-five patients (nine male, 36 female, mean age 
46 ± 14 years; range 23-74 years) with multilocular 
hemangioma and FNH were also retrospectively 
analyzed. All lesions were histologically proven by 
18-gauge core needle biopsy. 
Examination technique
Conventional ultrasound and CEUS were performed by 
five ultrasound systems: LOGIQ E9 (GE Healthcare, 
Milwaukee, WI, United States; C1-5 convex array 
probes, 1-5MHz), Acuson Sequoia (Siemens Healthcare, 
Erlangen, Germany, 3.5 MHz), Philips iU22 unit (Philips 
Healthcare, Bothell, WA, United States; C5-1 convex 
array probes, 1-5MHz), Technos MPX Scanner, and 
MyLab70 (Esaote, Genova, Italy; ca431 convex array 
probe 1-8 MHz).
CEUS was performed using contrast harmonic real 
time imaging at a low MI 0.05-0.30. Each examination 
lasted about 5 min after the bolus injection. The 
contrast agent used was SonoVue® (Bracco Imaging 
Spa, Milan, Italy). For each CEUS examination, a dose 
of 1.5-2.4 mL of SonoVue® was injected as a quick 
bolus via a 20 gauge intravenous catheter placed in 
the cubital vein, followed by 5-10 mL of 0.9% normal 
saline flush. Repeated injection of SonoVue® was 
performed when necessary. 
To characterize the lesion, SonoVue® enhancement 
during the arterial phase (10-30 s), portal venous 
(20-120 s), and late vascular phases (120-300 s) were 
evaluated[17]. All examinations were digitally recorded. 
Image analysis
All HEHE images were read by four independent 
radiologists (15, 17, 23, and 27 years of experience 
with abdominal ultrasound imaging) blinded to clinical 
and pathologic data in consensus. Criteria evaluated 
included number of lesions, maximum diameter, 
echogenicity (hyperechoic, hypoechoic, or isoechoic; 
homogeneous or heterogeneous; which were visually 
compared with the echogenicity of the surrounding 
liver parenchyma), shape (regular or lobulated), 
margin (ill- or well defined appearance), and color 
Doppler imaging features. Using CEUS, the pattern of 
contrast enhancement of the lesion in comparison to 
the surrounding liver parenchyma (hypoenhancing, 
hyperenhancing, isoenhancing), homogeneity of 
enhancement (homogeneous, heterogeneous), and 
additional features of enhancement during the arterial, 
portal venous, and late phases were noted as well, e.g., 
rim-like or peripheral nodular enhancement, central or 
eccentric arterial enhancement).
CEUS features of 45 patients of histologically 
proven multilocular liver hemangioma and FNH were 
also retrospectively evaluated to compare the CEUS 
features for differential diagnosis. Digital cineloops 
were registered both during baseline and post contrast 
US scanning. All cineloops were digitally stored in a 
PC based workstation connected to the ultrasound 
systems.
Pathologic examination
The final pathologic diagnosis was based on hematoxylin-
eosin stained sections and immunohistochemical staining 
results. The immunohistochemical staining included 
endothelial markers, such as CD 34, CD 31, and factor 
VIII-related antigen (FVIII Ag)[20].
Statistical analysis
Data are expressed as mean ± SD. All statistical 
analyses were performed with SPSS 17.0 software 
package (SPSS, Chicago, IL, United States). The χ 2 test 
was used to compare HEHE with liver hemangiomas 
and FNH in terms of enhancement pattern. For the 
features that played a statistically significant role in 
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Table 1  Baseline characteristics of patients included in our 
study
Characteristic HEHE 
(n  = 25)
Hemangioma and 
FNH (n  = 45)
Age (yr)
mean ± SD 46 ± 14 46 ± 14
Range 24-78 23-74
Male/female 8/17 9/36
Number of FLL (single/multiple) 3/22 0/45
Histological results
hepatic surgery   6   0
core needle biopsy 19 45
HEHE: Hepatic epithelioid haemangioendothelioma; FNH: Focal nodular 
hyperplasia; FLL: Focal liver lesions.
Dong Y et al . CEUS of HEHE
FLL was observed (2/25, 8%).
Color Doppler imaging detected branched intra-
lesional vessels in 84% (21/25) of HEHE. The Doppler 
spectrum was measured in 13 patients. The mean 
value of resistive index (RI) was 0.64 ± 0.07 (Figure 1 
and Table 2). 
CEUS features
On CEUS, HEHE presented peripheral rim-like (18/25, 
72%) (Figure 2) or heterogeneous hyperenhancement 
(7/25, 28%) at the arterial phase (Figure 3) and 
hypoenhancement (100%, 25/25) at PVLP (Figure 
4). Central unenhanced areas were observed in 72% 
(18/25) of HEHE in the late phases. After CEUS, more 
lesions could be detected in seven patients of HEHE 
than with conventional ultrasound. Liver hemangioma 
typically demonstrated peripheral nodular contrast 
enhancement in all patients, whereas FNH showed 
central or eccentric arterial blood supply in the arterial 
phase. In addition, in all patients, both entities showed 
hyperenhancement in the PVLP, a sign of the benign 
nature of the lesion. Compared to multilocular liver 
hemangioma and FNH, characteristic CEUS features of 
HEHE were peripheral rim-like hyperenhancement in 
the arterial phase and quick washout in the PVLP with 
a central unenhanced area in the late phase (P < 0.01) 
(Table 3).
The sensitivity for peripheral rim-like hyperen-
hancement at the arterial phase was 72%; for 
the differentiation diagnosis, we calculated sensitivity 
and specificity. A difference was considered statistically 
significant with P < 0.05.
RESULTS
Clinical and general pathologic features
All patients were incidentally found to have hepatic lesions 
by conventional ultrasound screening. Conventional 
laboratory tests [including transaminases, bilirubin, 
and gamma-glutamyl transpeptidase (gGT)] were 
within normal limits or only slightly elevated in all 
patients. Alpha-fetoprotein, carcinoembryonic antigen, 
and cancer antigen 19-9 as well as hepatitis B surface 
antigen and hepatitis C virus were negative respective 
of normal in all patients.
Final pathologic diagnosis of HEHE showed the 
typical fibrosclerotic center and cellular periphery on 
hematoxylin-eosin staining. Immunohistochemically, 
tumors were positive for at least one endothelial 
marker, including CD 34 (n = 20), CD 31 (n = 20), or 
FVIII Ag (n = 11).
Features with conventional ultrasound in HEHE
HEHE manifested as single (3/25, 12%) or multiple 
FLLs (22/25, 88%) with ill-defined margins on grayscale 
ultrasound. The lesions were mainly hypoechoic 
(23/25, 92%) to adjacent liver parenchyma, but a 
heterogeneous echogenicity with hypo- or hyperechoic 
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Figure 1  Multiple hepatic epithelioid hemangioendotheliomas in a 31 year female. A: Grayscale ultrasound showed a distinct hypoechoic focal liver lesion (FLL) 
(arrow); B: Multiple hypoechoic lesions (arrows) were also detected in this patient; C: Color Doppler imaging (CDFI) showed peripheral and intra-lesion color flow 
signals; D: The resistive index (RI) of color flow was 0.70.
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quick washout in the PVLP, it was 100%; for central 
unenhanced area at late phase, it was 72%; and for 
the combination of both, it was 85% (Table 3).
DISCUSSION
To the best of our knowledge, CEUS features of HEHE 
have not been well characterized. To date, only a few 
imaging studies have investigated HEHE, and most 
of them were limited patients series[4,15,21], and CEUS 
features of HEHE have been described only in a few 
patients[15,21,22]. In many patients, CEUS is the first 
and decisive imaging technique for detecting and 
characterizing liver tumors[23-25]. The use of ultrasound 
contrast agents improved detection and made it 
possible to assess the benign or malignant nature of 
liver tumors in most patients[13,26-28]. Previously, three 
forms of HEHE have been described: single nodular, 
multifocal nodular, and the diffuse type[1]. Consistent 
with our current study, most HEHE present as multiple 
FLL. After CEUS, more lesions could be detected 
in 7/25 (28%) patients[29]. As HEHE has ill-defined 
margins on grayscale ultrasound, CEUS may be 
helpful to detect more lesions with sharper and clearer 
margins.
In our current retrospective study, we discovered 
that CEUS reliably showed typical signs of HEHE in 
most patients with hyperenhancement in the arterial 
phase and hypoenhancement in the PVLP, which might 
be useful in determining whether a biopsy is necessary 
for suspected malignant lesions. In correlation with 
pathologic classification, histologically, HEHE possesses 
two distinctive characteristics, which are directly 
related to the echogenicity and enhancement pattern 
of HEHE on ultrasound images[1,20,30,31]. First, HEHE 
are composed of dendritic and epithelioid cells with 
intracytoplasmic lumina containing red blood cells. 
However, the peripheral proliferation remains active 
and forms numerous arterial-venous shunts, which 
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Table 2  Conventional ultrasound features of hepatic 
epithelioid haemangioendothelioma and hemangioma/Focal 
nodular hyperplasia  n  (%)
Characteristic HEHE 
(n  = 25)
Hemangioma/FNH
(n  = 45)
Number of nodules (single/multiple) 3/22 0/45
Size of nodules (mm)
    mean ± SD 41.5 ± 25.6 50.4 ± 25.7
    range 12-120 20-138
Echogenicity of nodules
   Hyperechoic 2 (8) 19 (42.2)
   Hypoechoic 23 (92)   9 (20.0)
   Isoechoic 0 17 (37.8)
   Homogenous/heterogeneous 9/16 15/30
HEHE: Hepatic epithelioid haemangioendothelioma; FNH: Focal nodular 
hyperplasia.
Figure 2  Contrast-enhanced ultrasound feature of hepaticepithelioid 
hemangioendothelioma in a 31 year female. A: Rim-like enhancement. In 
arterial phase (16 s after injection of SonoVue), peripheral rim-like enhancement 
was demonstrated; B: In peak enhancement (24 s after injection of SonoVue), 
the degree of the rim-like enhancement was equivalent to the liver parenchyma; 
C: In portal venous phase (45 s after injection of SonoVue), the lesion washed 
out quickly and showed hypoenhancement; D: In late phase (65 s after injection 
of SonoVue), the lesion remained hypoenhanced with central unenhanced area.
D
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Figure 3  Contrast-enhanced ultrasound feature of hepatic epithelioid hemangioendothelioma in a 25 year female. A: Heterogeneous enhancement pattern. In 
the arterial phase (16 s after injection of SonoVue), the lesion showed heterogeneous enhancement; B: The enhancement gradually decreased (22 s after injection of 
SonoVue); C: In the portal venous phase (40 s after injection of SonoVue), the lesion washed out fast than the liver parenchyma and showed hypoenhancement. D: In 
the late phase (165 s after injection of SonoVue), the lesion remained hypoenhanced.
Figure 4  Contrast-enhanced ultrasound feature of hepatic epithelioid hemangioendothelioma in right lobe of liver. A: Grayscale ultrasound showed a 
hypoechoic focal liver lesions (FLL); B:  In the arterial phase the lesion showed heterogeneous enhancement (22 s after injection of SonoVue); C: In the portal venous 
phase (53 s after injection of SonoVue), the lesion washed out fast and showed hypoenhancement. 
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could account for the fast rim-like enhancement in the 
arterial phase and quick washout in the PVLP during 
CEUS[7]. Second, tumor cells and stroma of HEHE 
exist in variable proportions, and the central stromal 
portion of the lesion can vary from myxoid to densely 
fibrotic. With the growth of the tumor, the central 
stroma degenerate gradually and become sclerotic 
as the blood supply decreases[20]. In our results, 
hypoenhancement with central unenhanced area at 
PVLP of CEUS was mostly common in HEHE. Moreover, 
additional lesions were detected at CEUS, leading to 
improvements in liver staging.
Alomari et al[32] first described the lollipop sign 
as a new cross-sectional sign of HEHE on computed 
tomography (CT) and magnetic resonance imaging 
(MRI): a well-defined peripherally enhancing (or 
non-enhancing) lesion with an avascular core on 
enhanced images (the candy in the lollipop) and a 
histologically occluded vein (the stick). Concerning the 
CT imaging, focal calcifications were reported in 20% 
of patients; capsular retraction was in 10%-25% of 
patients[20]. The lesions demonstrated peripheral rim-
like hyperenhancement in the arterial phase with even 
stronger enhancement in the portal venous phase by 
contrast enhanced MRI. Central areas of reduced signal 
may correspond to areas of hemorrhage, coagula-
tion necrosis, and calcification[7]. We showed that 
peripheral rim-like hyperenhancement in the arterial 
phase and hypoenhancement in the PVLP with central 
unenhanced areas could be detected in 72% HEHE 
patients. Therefore, the contrast enhanced image 
modalities demonstrate a similar enhancement pattern 
of this disease. CEUS can be considered at least equal 
to, and in some ways (real time observation, no 
radiation, less expensive) superior to, CT and MRI as a 
diagnostic tool[33].
Most of the HEHE lesions were multinodular (88%) 
and hypoechoic (92%) in our current study. As set out 
in the current literature and in textbooks, the origin 
of hypoechoic lesions is considerably more varied and 
confusing than other lesions[13,23]. All hypoechogenic 
lesions should be investigated using a contrast 
enhanced imaging technique[16,18]. Evaluation with 
CEUS in the PVLP is determinant in this context, and 
contrast medium hypoenhancement in the late phase 
is a decisive indication for liver biopsy[23]. 
HEHE has a variable clinical and biological course 
compared to benign endothelial tumors (hemangiomas) 
and malignant angiosarcomas with a slowly pro-
gressive phenotype. The tumor can even be difficult 
to diagnose based on biopsy specimens[34]. CEUS 
differentiation of different liver tumors is essential 
because of different therapeutic approaches[35]. HEHE 
should be differentiated from atypical multilocular 
liver hemangioma and FNH, because both of them 
could demonstrate as multilocular hypoechoic liver 
lesions. Although benign FLLs are commonly iso- 
or hyperenhancing in the PVLP, malignant primary 
and secondary liver tumors almost always show 
hypoenhancement in the PVLP[18,19]. Based on results 
of our retrospective analysis, we believe that peripheral 
rim-like hyperenhancement at the arterial phase and 
quick washout at the PVLP with central unenhanced 
area are hallmark features that suggest a diagnosis 
of possible HEHE. In contrast, both multilocular 
hemangiomas and FNH showed hyperenhancement 
and remained iso or hyperenhanced in PVLP. 
Furthermore, in the clinical setting, factors helpful 
for the differential diagnosis of HEHE are a medical 
history without extrahepatic malignant tumor, patients 
with no symptoms, and laboratory tests[35]. 
In conclusion, CEUS imaging findings reliably 
compile typical signs of HEHE, allowing for effective 
differentiation with other multilocular hypoechoic 
hepatic lesions, including liver hemangioma and FNH. 
CEUS can help to improve the diagnostic confidence 
of HEHE, a rare hepatic tumor, and the liver staging of 
the disease to guide additional diagnostic work-up.
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investigated HEHE, and most of them were limited patients series.
Research frontiers
This is the first report on the CEUS features of HEHE.
4747 May 21, 2016|Volume 22|Issue 19|WJG|www.wjgnet.com
Table 3  Contrast enhanced ultrasound imaging features of 
hepatic epithelioid haemangioendothelioma and multilocular 
hemangioma/ focal nodular hyperplasia  n  (%)
Characteristic HEHE
(n = 25 patients)
Hemangioma/FNH
(n  = 45 patients)
Arterial phase
   Rim like hyperenhancement 18 (72) 0
   Heterogeneously 
   hyperenhancement
  7 (28) 6 (13.3)
   Peripheral nodular 
   enhancement
0 All hemangioma
   Central arterial blood supply All FNH
Portal-venous phase
   Hyperenhancement 0 100 (100.0%)
   Hypoenhancement 25 (100) 0
   Isoenhancement 0 0
Late phase
   Hyperenhancement 0 45 (100.0%)
   Hypoenhancement 25 (100) 0
   Isoenhancement 0 0
Sensitivity
   Rim like hyperenhancement 18/25 (72) 0
   Hypoenhancement at portal 
   venous phase
  25/25 (100) 0
Central unenhanced area at late 
phase
   Yes 18 (72) 13 (28.9)
   No   7 (28) 32 (71.1)
CEUS: Contrast enhanced ultrasound; HEHE: Hepatic epithelioid 
haemangioendothelioma; FNH: Focal nodular hyperplasia.
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effectively it from other multilocular hypoechoic hepatic lesions, including liver 
hemangioma and focal nodular hyperplasia. 
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Terminology
CEUS allows for the differentiation of most benign and malignant liver tumors in 
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